Kraut Roni, Lundby Carina, Babenko Oksana, Kamal Ahmad, Sadowski Cheryl A
Department of Family Medicine, University of Alberta, Edmonton, Canada.
Hospital Pharmacy Funen, Odense University Hospital, Odense C, Denmark.
Am Heart J Plus. 2022 Jun 30;17:100166. doi: 10.1016/j.ahjo.2022.100166. eCollection 2022 May.
The management of hypertension in frail older adults remains controversial, as these patients are underrepresented in clinical trials and practice guidelines. Overtreatment may cause harm while undertreatment may lead to greater risk of cardiovascular events. Our research aims to examine this controversy and provide guidance regarding deprescribing decisions in frail older adults.
Current evidence suggests that there may be minimal cardiovascular benefit and significant harm of antihypertensive medication in the frail older adult population. A minority of hypertension guidelines provide sufficient recommendations for frail older adults, and there are limited tools available to guide clinical decision-making.
Randomized controlled trials and well-designed observational studies are needed to confirm the benefit-to-harm relationship of antihypertensive medication in frail older adults. Decision tools that comprehensively address antihypertensive deprescribing would be advantageous to help clinicians with hypertension management in this population. Clinicians should engage in shared decision-making with the patient and family to ensure that decisions regarding antihypertensive deprescribing best meet the needs of all involved.
体弱老年人高血压的管理仍存在争议,因为这些患者在临床试验和实践指南中的代表性不足。过度治疗可能会造成伤害,而治疗不足可能会导致心血管事件风险增加。我们的研究旨在探讨这一争议,并为体弱老年人的减药决策提供指导。
目前的证据表明,在体弱老年人群中,抗高血压药物可能带来的心血管益处极小,且存在显著危害。少数高血压指南为体弱老年人提供了充分的建议,且用于指导临床决策的工具有限。
需要进行随机对照试验和精心设计的观察性研究,以确认抗高血压药物在体弱老年人中的利弊关系。全面解决抗高血压药物减药问题的决策工具,将有助于临床医生管理该人群的高血压。临床医生应与患者及其家属共同参与决策,以确保抗高血压药物减药决策能最好地满足所有相关人员的需求。